1.635
iBio Inc (IBIO) 最新ニュース
Top iBio (IBIO) Competitors 2026 - MarketBeat
IBIO Stock Price, Quote & Chart | IBIO INC (NASDAQ:IBIO) - ChartMill
iBio (NASDAQ: IBIO) substitutes SILV Fund after 876,340‑share transfer - Stock Titan
IBIO stock is soaring today after iBio's muscle-preserving drug receives approval for human trial in Australia - MSN
IBIO (IBIO) price target increased by 18.73% to 5.47 - MSN
iBio (IBIO) Receives Regulatory Clearance to Initiate Phase 1 Trial of IBIO-600 - Yahoo Finance
10 Best NASDAQ Growth Stocks to Buy and Hold Forever - Insider Monkey
IBIO (iBio Inc.) falls 2.37% today after Q1 2026 EPS lands slightly below consensus estimates.Revenue Guidance - Xã Châu Thành
IBIO (iBio Inc.) reports 77.8 percent year over year Q1 2026 revenue growth, shares edge higher.Growth Acceleration - Cổng thông tin điện tử Tỉnh Sơn La
iBio, Inc. 8-K/A Filing Details: Company Information, Address, and Stock Listing (April 8, 2026) - Minichart
iBio (IBIO) clarifies warrant expirations and advances IBIO-600 Phase 1 trial - Stock Titan
IBIO Stock Chart | IBIO INC (NASDAQ:IBIO) - ChartMill
LifeSci Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
Chardan Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
Is iBio (IBIO) Stock Stable Now | Price at $2.17, Up 0.23%Aggressive Growth Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update - ADVFN
iBio Inc. (IBIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Ibio (IBIO) Receives a Buy from Chardan Capital - The Globe and Mail
IBIO: Chardan Capital Maintains 'Buy' Rating with $5.00 Price Ta - GuruFocus
Ibio’s IBIO-600 cleared to enter clinic in Australia for obesity - BioWorld News
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia - Sahm
iBio receives approval to start phase 1 trial of IBIO-600 By Investing.com - Investing.com India
Is iBio (IBIO) Stock Risky Now | Price at $2.21, Down 1.12%Alpha Picks - Cổng thông tin điện tử tỉnh Lào Cai
iBio Receives Regulatory Clearance to Begin Phase 1 Trial of IBIO-600, a Long-Acting Anti-Myostatin Antibody for Obesity, in Australia 1 - Minichart
iBio, Inc. (IBIO) Stock Price, News, Quote & History - Yahoo! Finance Canada
iBio Advances to Clinical Stage With IBIO-600 Trial - TipRanks
iBio, Inc. (IBIO) stock price, news, quote and history - Yahoo Finance UK
IBIO Stock Is Soaring Today After iBio's Muscle-Preserving Drug Receives Approval For Human Trial In Australia - Stocktwits
Regulators clear iBio (NASDAQ: IBIO) to launch first-in-human IBIO-600 trial - Stock Titan
iBio receives approval to start phase 1 trial of IBIO-600 - Investing.com
Street Watch: Is iBio Inc a speculative investment2026 Investor Takeaways & Real-Time Volume Spike Alerts - baoquankhu1.vn
IBIO Technical Analysis | Trend, Signals & Chart Patterns | IBIO INC (NASDAQ:IBIO) - ChartMill
Aug Selloffs: Will iBio Inc benefit from green energy policiesInsider Selling & Real-Time Buy Zone Alerts - baoquankhu1.vn
FRA:0JV0 PB Ratio: 1.01 — 33% Below Median - GuruFocus
IBIO Should I Buy - Intellectia AI
iBio Inc. (0JV0.SG) cash flow - Yahoo Finance UK
Can iBio Inc stock double in the next yearQuarterly Performance Summary & Entry and Exit Point Strategies - baoquankhu1.vn
Insider List - GuruFocus
Insider Buying: Marc Banjak Acquires Additional Shares of iBio I - GuruFocus
大文字化:
|
ボリューム (24 時間):